Cross-cohort analysis identified an immune checkpoint-based signature to predict the clinical outcomes of neuroblastoma.

J Immunother Cancer · 2023 · PMC10163522 · PMID 37130627

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginally significantno p-value reported

Concordant with these investigations, we found that TIM-3 was expressed in tumor-associated immune cells of NB tissues and that high expression of TIM-3 was a significant risk factor for a shorter OS, as well as a marginally significant factor for a poor EFS in the discovery set.

also in 26,082 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.